1. Home
  2. CRNX vs FICO Comparison

CRNX vs FICO Comparison

Compare CRNX & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$84.50

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Fair Isaac Corproation

FICO

Fair Isaac Corproation

HOLD

Current Price

$1,100.43

Market Cap

22.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
FICO
Founded
2008
1956
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
22.3B
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
CRNX
FICO
Price
$84.50
$1,100.43
Analyst Decision
Strong Buy
Buy
Analyst Count
8
13
Target Price
$76.75
$1,689.92
AVG Volume (30 Days)
2.9M
374.6K
Earning Date
05-07-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.78
EPS
N/A
28.12
Revenue
$1,039,000.00
$1,032,475,000.00
Revenue This Year
$720.10
$27.28
Revenue Next Year
$184.67
$16.97
P/E Ratio
N/A
$37.13
Revenue Growth
N/A
N/A
52 Week Low
$28.73
$870.01
52 Week High
$84.54
$1,998.01

Technical Indicators

Market Signals
Indicator
CRNX
FICO
Relative Strength Index (RSI) 90.44 46.39
Support Level $83.47 $1,086.27
Resistance Level N/A $1,117.39
Average True Range (ATR) 0.26 61.12
MACD -1.53 -10.55
Stochastic Oscillator 82.26 24.25

Price Performance

Historical Comparison
CRNX
FICO

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

Share on Social Networks: